ARCHIVES

Phase III Trial Fails to Extend OS After Meeting Primary Endpoint Of Durable Response Rate

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

In Brief” McKenna New ACS President, Lemaistre President Elect; Michael Potter Wins Albert Lasker Award

November 23, 1984

DOD funds $4.2 million gynecologic oncology research program at four institutions.

July 2, 2004

SWOG Phase III Trial To Test Treatment For Inoperable, Locally Advanced NSCLC

September 28, 2001

Ibrutinib Demonstrates 71% ORR In Phase Ib/II CLL and SLL Study

July 26, 2013

NCI Official Says He Hopes to “Put More Money” Into SPOREs.

April 14, 2006

In Brief: Community Planning Contracts New Review, Implementation Projects Still In Negotiation

June 4, 1976